Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382482 | 0.87 | CA12 (0.47) | MAPTLMNANPC1RAB9ACLK1 | |
| SCHEMBL7388942 | 0.86 | ALOX5 (0.43) | CCR2CCR3MAPTLMNAALOX5 | |
| SCHEMBL5209506 | 0.86 | CCR2 (0.46) | CCR2CCR3MAPTTP53LMNA | |
| SCHEMBL7697013 | 0.85 | NPC1 (0.41) | MAPTTP53LMNAALOX5NPC1 | |
| SCHEMBL7382857 | 0.85 | MAPT (0.43) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL7380758 | 0.85 | CA12 (0.47) | MAPTLMNANPC1RAB9ACLK1 | |
| SCHEMBL5550241 | 0.84 | ALDH1A1 (0.52) | MAPTTP53LMNAALOX5NPC1 | |
| SCHEMBL7698975 | 0.83 | CA12 (0.52) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL7702964 | 0.83 | NPC1 (0.42) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL7702467 | 0.82 | SMN1; SMN2 (0.45) | MAPTTP53LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1760054-A2 | Process for producing cyclic compound | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7038042-B2 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20050096475-A1 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| US-6864367-B2 | Process for producing cyclic compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
| US-20030040632-A1 | Process for producing cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1266881-A1 | PROCESS FOR PRODUCING CYCLIC COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6413947-B1 | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040632-A1 | Process for producing cyclic compound | CTH, DOHH, SLC39A11 | CCR2 194/4885CCR3 345/4885MAPT 4452/4885 |
| US-20050096475-A1 | Process for producing cyclic compound | SLC39A11, CYP4F11, WEE1 | CCR2 675/4885CCR3 1007/4885MAPT 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.